We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Factory Location: 3 Block,No.333 Hanyang Road, Shizhong District, 641000, Neijiang City, Shizhong, China
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Payment Terms: T/T
Ingredients: Active ingredient: paclitaxel Molecular formula: C47H51NO14
Molecular weight: 853.9
This product is a multi-use formulation specification. Each ml of sterile injectable solution contains 6 mg of paclitaxel, 527 mg of purified polyoxyethylene castor oil (Cremophor ELP) and 49.7% (volume/volume) absolute ethanol. Properties: This product is colorless to yellowish viscous liquid. Indications: First-line and subsequent treatment of advanced ovarian cancer.
Patients with node-positive breast cancer are treated as adjuvant therapy after standard doxorubicin-containing regimens combined with chemotherapy.
Patients with breast cancer with metastatic breast cancer who have failed chemotherapy in combination with chemotherapy or who have relapsed within 6 months of adjuvant chemotherapy.
First-line treatment for patients with non-small cell lung cancer.
Second-line treatment of AIDS-associated Kaposi's sarcoma. Dosage: Note: It is not recommended to contact undiluted concentrated chemicals with plasticized polyvinyl chloride (PVC) vessels used to prepare drip solutions. In order to reduce the patient's exposure to DEHP plastic substances [di-(2-ethylhexyl)phthalate, di-(2-ethylhexy)phthalate) that may be released by polyvinyl chloride drip bags or other devices, the diluted solution should be stored in glass bottles, polypropylene bottles or (polypropylene, polyolefin) plastic bags, and polyethylene-lined drug delivery equipment should be used for instillation.
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
